Biocardia (BCDA): CEO bought ~$402

~$402

Approx. value · 300 sh @ $1.34

269K

Holds after · shares reported

Traded

Jan 21, 2026

Filed

Jan 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 2, 2025Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote (and 1 more item)“On December 2, 2025, the Board of Directors (the “Board”) of BioCardia, Inc. (the “Company” or “BioCardia”) appointed Marvin Slosman as a member of the Board, with an initial term beginning immediately and expiring at BioCardia’s 2028 Annual Meeting of Shareholders, or until his successor is duly elected and qualified.”
2. Dec 16, 2025InsiderCEO purchased ~$274 of BCDA shares in the open market
3. Dec 17, 2025InsiderCEO purchased ~$1.2K of BCDA shares in the open market
4. Jan 20, 2026InsiderCEO purchased ~$792 of BCDA shares in the open market
5. Jan 21, 2026 · this disclosureInsiderCEO purchased ~$402 of BCDA shares in the open market

What came next

1. Feb 4, 2026InsiderCEO purchased ~$5.7K of BCDA shares in the open market
2. Mar 24, 2026Company filing · Form 8-K · ResultsReported its results
3. Mar 24, 2026InsiderCEO purchased ~$744 of BCDA shares in the open market
4. Mar 25, 2026InsiderCEO purchased ~$366 of BCDA shares in the open market
5. Apr 10, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On April 10, 2026, BioCardia, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule…”
6. Apr 20, 2026InsiderCEO purchased ~$738 of BCDA shares in the open market
7. Apr 21, 2026InsiderCEO purchased ~$492 of BCDA shares in the open market
8. Apr 29, 2026InsiderCEO purchased ~$5.5K of BCDA shares in the open market
9. May 15, 2026Company filing · Form 8-K · ResultsReported its results
10. May 15, 2026InsiderCEO purchased ~$5.2K of BCDA shares in the open market
11. May 18, 2026InsiderCEO purchased ~$5.2K of BCDA shares in the open market
12. May 19, 2026InsiderCEO purchased ~$190 of BCDA shares in the open market
13. May 20, 2026InsiderCEO purchased ~$1.4K of BCDA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Biocardia

For Biocardia, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCDA page.

Other recent filings by Peter Altman, President and CEO

• SEC Form 4 at Biocardia (BCDA)Oct 20, 2026
• SEC Form 4 at Biocardia (BCDA)Oct 20, 2026
• SEC Form 4 at Biocardia (BCDA)Sep 30, 2026
• SEC Form 4 at Biocardia (BCDA)Sep 24, 2026
• SEC Form 4 at Biocardia (BCDA)Sep 5, 2026

The full history of Peter Altman, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Biocardia

• SEC Form 4Oct 20, 2026
• SEC Form 4Oct 20, 2026
• SEC Form 4Sep 30, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 5, 2026
• SEC Form 4Aug 18, 2026

Everything OQRO holds on this company is on its BCDA page.